<DOC>
	<DOCNO>NCT00641927</DOCNO>
	<brief_summary>This study examine relative safety benefit antidepressant therapy ( versus recommend mood stabilizer therapy ) bipolar type II major depressive episode . We hypothesize antidepressant therapy superior mood stabilizer therapy little difference treatment emergent manic symptom .</brief_summary>
	<brief_title>Antidepressant Therapy Bipolar II Major Depression</brief_title>
	<detailed_description>Bipolar type II ( BP II ) major depressive episode ( MDE ) , affect 2.5 % US adult population result estimate healthcare cost $ 40 billion annually . BP II disorder distinct clinical entity differs BP I disorder , characterize preponderance MDEs result particularly high morbidity mortality rate . The treatment BP II MDE remain challenge clinician . Concerns antidepressant drug ( AD ) induce manic switch episode lead current practice guideline recommend treat BP II MDE mood stabilizer ( MS ) monotherapy avoid AD monotherapy . To date , control clinical trial test validity empirical guideline . Results preliminary BP II MDE study show fluoxetine monotherapy may safe effective initial treatment BP II MDE low manic switch rate . Based upon observation , ask ( Specific aim # 1 ) : `` What relative safety efficacy initial AD monotherapy vs. MS monotherapy BP II MDE ? '' `` What relative manic switch rate initial AD vs. MS monotherapy BP II MDE ? '' To answer question , patient BP II MDE treat 12-week , randomize , parallel group comparison venlafaxine monotherapy vs. lithium monotherapy . We hypothesize AD monotherapy superior efficacy vs. MS monotherapy , similar manic switch rate among treatment condition . If hypothesis correct , believe result may important public health impact current practice guideline treat BP II MDE .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>men woman ( race ethnicity ) great equal to18 year age , DSM IV diagnosis BP II disorder , Current DSM IV MDE , HAMD17 score great equal 16 , Drug free prior psychotropic medication great equal 7 day ( 2 week MAOIs ) History mania , Other primary DSM IV Axis I diagnosis , Alcohol drug dependence within 3 month , History nonresponse EffexorXR lithium present MDE , History allergic reaction EffexorXR lithium , Medical contraindication treatment EffexorXR lithium , Unstable medical condition , Pregnant breastfeed woman , Women childbearing potential use medically approve form contraception , Actively suicidal require hospitalization , Requiring concurrent antidepressant , neuroleptic mood stabilizer therapy , Prior investigational study within 4 week start active therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>bipolar disorder</keyword>
	<keyword>bipolar type II disorder</keyword>
	<keyword>antidepressant</keyword>
	<keyword>mood stabilizer</keyword>
	<keyword>venlafaxine</keyword>
	<keyword>lithium carbonate</keyword>
</DOC>